Moomoo AI 已提取核心信息
On December 31, 2023, a Schedule 13G was filed with the SEC by Anson Funds Management LP, Anson Management GP LLC, Tony Moore, Anson Advisors Inc., Amin Nathoo, and Moez Kassam, indicating a collective beneficial ownership of 9.8% of Zyversa Therapeutics, Inc.'s common stock. This group, consisting of investment advisors and directors from Texas and Ontario, Canada, has shared voting and dispositive power over 160,671 shares of the biopharmaceutical company. The filing, which was completed on February 14, 2024, asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Zyversa Therapeutics. The Schedule 13G is a regulatory document required by the SEC when parties exceed certain thresholds of ownership in a company's stock.
On December 31, 2023, a Schedule 13G was filed with the SEC by Anson Funds Management LP, Anson Management GP LLC, Tony Moore, Anson Advisors Inc., Amin Nathoo, and Moez Kassam, indicating a collective beneficial ownership of 9.8% of Zyversa Therapeutics, Inc.'s common stock. This group, consisting of investment advisors and directors from Texas and Ontario, Canada, has shared voting and dispositive power over 160,671 shares of the biopharmaceutical company. The filing, which was completed on February 14, 2024, asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Zyversa Therapeutics. The Schedule 13G is a regulatory document required by the SEC when parties exceed certain thresholds of ownership in a company's stock.
2023年12月31日，安森基金管理有限责任公司、安森管理集团有限责任公司、托尼·摩尔、安森顾问公司、阿明·纳索和莫兹·卡萨姆向美国证券交易委员会提交了附表13G，表示拥有Zyversa Therapeutics, Inc.9.8％的集体实益所有权。”s 普通股。该小组由来自加拿大德克萨斯州和安大略省的投资顾问和董事组成，对这家生物制药公司的160,671股股票共享投票权和处置权。该文件于2024年2月14日完成，声称这些股票是在正常业务过程中收购的，不是为了改变或影响Zyversa Therapeutics的控制权。附表13G是当各方超过公司股票所有权的特定门槛时美国证券交易委员会要求的监管文件。
2023年12月31日，安森基金管理有限责任公司、安森管理集团有限责任公司、托尼·摩尔、安森顾问公司、阿明·纳索和莫兹·卡萨姆向美国证券交易委员会提交了附表13G，表示拥有Zyversa Therapeutics, Inc.9.8％的集体实益所有权。”s 普通股。该小组由来自加拿大德克萨斯州和安大略省的投资顾问和董事组成，对这家生物制药公司的160,671股股票共享投票权和处置权。该文件于2024年2月14日完成，声称这些股票是在正常业务过程中收购的，不是为了改变或影响Zyversa Therapeutics的控制权。附表13G是当各方超过公司股票所有权的特定门槛时美国证券交易委员会要求的监管文件。
有用
没用